scholarly article | Q13442814 |
P6179 | Dimensions Publication ID | 1001340407 |
P356 | DOI | 10.1038/LEU.2015.138 |
P932 | PMC publication ID | 4610040 |
P698 | PubMed publication ID | 26055303 |
P50 | author | Johannes Zuber | Q47713758 |
Gregor Eisenwort | Q50623922 | ||
Gregor Hoermann | Q50930011 | ||
Peter Valent | Q56697676 | ||
Harald Herrmann | Q56940149 | ||
Irina Sadovnik | Q56979840 | ||
Emir Hadzijusufovic | Q38327164 | ||
P2093 | author name string | D Radia | |
A Reiter | |||
J E Bradner | |||
T Hoffmann | |||
W R Sperr | |||
H-P Horny | |||
M Arock | |||
L Müllauer | |||
K Blatt | |||
G Wedeh | |||
J Schwaab | |||
S Cerny-Reiterer | |||
P2860 | cites work | Bromodomain protein Brd4 binds to GTPase-activating SPA-1, modulating its activity and subcellular localization | Q24561478 |
One-step detection of c-kit point mutations using peptide nucleic acid-mediated polymerase chain reaction clamping and hybridization probes | Q24685763 | ||
BRD4 is an atypical kinase that phosphorylates serine2 of the RNA polymerase II carboxy-terminal domain | Q28116760 | ||
BET domain co-regulators in obesity, inflammation and cancer | Q28269301 | ||
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia | Q29617201 | ||
Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors | Q33384073 | ||
Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm | Q70972826 | ||
Morphologic properties of neoplastic mast cells: delineation of stages of maturation and implication for cytological grading of mastocytosis | Q73936505 | ||
Systemic mastocytosis | Q75343552 | ||
The histone code and treatments for acute myeloid leukemia | Q83590327 | ||
Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder | Q33784323 | ||
Diagnostic criteria and classification of mastocytosis: a consensus proposal | Q33948617 | ||
BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia | Q34033206 | ||
Mast cell leukemia: report of a case and review of the literature | Q34165793 | ||
Diagnosis of mastocytosis: general histopathological aspects, morphological criteria, and immunohistochemical findings. | Q34264299 | ||
Unique effects of KIT D816V in BaF3 cells: induction of cluster formation, histamine synthesis, and early mast cell differentiation antigens. | Q34293285 | ||
Clonal analysis of NRAS activating mutations in KIT-D816V systemic mastocytosis | Q34612654 | ||
Mastocytosis: state of the art. | Q34641105 | ||
An optimized microRNA backbone for effective single-copy RNAi | Q35065928 | ||
Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria | Q35101794 | ||
Diagnosis and classification of mast cell proliferative disorders: delineation from immunologic diseases and non-mast cell hematopoietic neoplasms. | Q35829710 | ||
Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. | Q35848377 | ||
On the way to targeted therapy of mast cell neoplasms: identification of molecular targets in neoplastic mast cells and evaluation of arising treatment concepts. | Q35854970 | ||
KIT mutations in mastocytosis and their potential as therapeutic targets | Q36576453 | ||
Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria | Q36835061 | ||
Mast cells and mastocytosis | Q36835143 | ||
Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia AML. | Q36926120 | ||
Expression of activated STAT5 in neoplastic mast cells in systemic mastocytosis: subcellular distribution and role of the transforming oncoprotein KIT D816V. | Q37462729 | ||
c-Myc inhibition prevents leukemia initiation in mice and impairs the growth of relapsed and induction failure pediatric T-ALL cells | Q37585215 | ||
Pathogenesis, classification and treatment of mastocytosis: state of the art in 2010 and future perspectives. | Q37810130 | ||
Tyrosine kinase inhibitors in the treatment of systemic mastocytosis. | Q37884959 | ||
Targeting epigenetic readers in cancer. | Q38034797 | ||
Mast cell leukemia | Q38067698 | ||
Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product | Q38315689 | ||
A new human mast cell line expressing a functional IgE receptor converts to tumorigenic growth by KIT D816V transfection | Q39010730 | ||
Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cells. | Q39033630 | ||
KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib | Q39523051 | ||
Polo-like kinase-1 as a novel target in neoplastic mast cells: demonstration of growth-inhibitory effects of small interfering RNA and the Polo-like kinase-1 targeting drug BI 2536. | Q39606792 | ||
Midostaurin (PKC412) inhibits immunoglobulin E-dependent activation and mediator release in human blood basophils and mast cells | Q39782974 | ||
Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT. | Q40048837 | ||
Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis | Q40325513 | ||
Establishment of an immature mast cell line from a patient with mast cell leukemia | Q41296878 | ||
Mutation analysis of C-KIT in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis. | Q43622703 | ||
Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit | Q44539087 | ||
Comprehensive mutational profiling in advanced systemic mastocytosis | Q46716443 | ||
PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects | Q46724516 | ||
The effects of dasatinib on IgE receptor-dependent activation and histamine release in human basophils | Q46818989 | ||
P433 | issue | 11 | |
P921 | main subject | mast cell | Q191989 |
P304 | page(s) | 2230-2237 | |
P577 | publication date | 2015-06-09 | |
P1433 | published in | Leukemia | Q6534498 |
P1476 | title | Identification of bromodomain-containing protein-4 as a novel marker and epigenetic target in mast cell leukemia | |
P478 | volume | 29 |
Q90292270 | CD44 is a RAS/STAT5-regulated invasion receptor that triggers disease expansion in advanced mastocytosis |
Q58617727 | Development and evaluation of a novel series of Nitroxoline-derived BET inhibitors with antitumor activity in renal cell carcinoma |
Q48104415 | Drug-induced inhibition of phosphorylation of STAT5 overrides drug resistance in neoplastic mast cells. |
Q64103896 | In vitro and in vivo efficacy of an anti-CD203c conjugated antibody (AGS-16C3F) in mouse models of advanced systemic mastocytosis |
Q41771583 | Inhibition of the BET family of epigenetic reader proteins: A novel principle for modulating gene expression in IgE-activated mast cells |
Q38777126 | Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts |
Q47930594 | Midostaurin: a magic bullet that blocks mast cell expansion and activation |
Q59810100 | Preclinical human models and emerging therapeutics for advanced systemic mastocytosis |
Q41061871 | Targeted Treatment Options in Mastocytosis |
Search more.